Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CTH | P32929 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9662640 | 0.85 | KMT2A (0.60) | KMT2AHTTBACE1CYP1A2HIF1A | |
| SCHEMBL9665192 | 0.82 | HTT (0.70) | KMT2AHTTCYP1A2TSHR | |
| SCHEMBL13439527 | 0.77 | KMT2A (0.49) | KMT2AHTTBACE1CYP1A2HIF1A | |
| SCHEMBL10137633 | 0.71 | KMT2A (0.58) | KMT2AHTTBACE1CYP1A2HIF1A | |
| SCHEMBL18576562 | 0.70 | KMT2A (0.57) | KMT2AHTTBACE1CYP1A2HIF1A | |
| SCHEMBL1765168 | 0.69 | — | — | |
| SCHEMBL9326232 | 0.68 | KMT2A (0.61) | KMT2AHTTBACE1 | |
| SCHEMBL22860806 | 0.68 | KMT2A (0.61) | KMT2AHTTBACE1 | |
| SCHEMBL13640164 | 0.68 | KMT2A (0.43) | KMT2A | |
| SCHEMBL78947 | 0.67 | LMNA (0.48) | KMT2ACYP1A2HIF1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5128467-A | Immunomodulation, liver disorders | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1992-07-07 | — | — | US | disclosed |
| US-5082836-A | Autoimmune diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1992-01-21 | — | — | US | disclosed |
| US-5041435-A | Treatment of Liver Disorders and Autoimmune Diseases | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1991-08-20 | — | — | US | disclosed |
| EP-0356006-A1 | Cyclic sulfur-containing compounds | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1990-02-28 | — | — | EP | disclosed |